- Future Students
- DVM degree program
- Graduate Programs
- Request information
- Contacts, Map, and Directions
- Current Students
- Faculty & Staff
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.
|Title||Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.|
|Publication Type||Journal Article|
|Year of Publication||1995|
|Authors||Fox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO|
|Date Published||1995 Summer|
|Keywords||Acetylmuramyl-Alanyl-Isoglutamine, Adenocarcinoma, Animals, Antineoplastic Agents, Cat Diseases, Cats, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Infusions, Intravenous, Liposomes, Male, Mammary Neoplasms, Animal, Mastectomy, Radical, Neoplasm Staging, Phosphatidylethanolamines, Survival Rate|
Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p < 0.02), and overall survival (p < 0.005) when compared with clinical stage III cats.
|Alternate Journal||Cancer Biother.|